Results 11 to 20 of about 53,090 (292)

Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells

Biomedicines, 2023
Background: Therapeutic options for CD19+ relapses after anti-CD19 CAR-T cells are still debated; second infusion of anti-CD19 CAR-T cells, therapeutic antibodies, or targeted therapies can be discussed.
Audrey Grain, Jocelyn Ollier, Thierry Guillaume, Patrice Chevallier, Baptiste Le Calvez, Marion Eveillard, Béatrice Clémenceau   +6 more
doaj   +2 more sources

Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. [PDF]

PLoS ONE, 2013
Clinical trials targeting CD19 on B-cell malignancies are underway with encouraging anti-tumor responses. Most infuse T cells genetically modified to express a chimeric antigen receptor (CAR) with specificity derived from the scFv region of a CD19 ...
Bipulendu Jena, Sourindra Maiti, Helen Huls, Harjeet Singh, Dean A Lee, Richard E Champlin, Laurence J N Cooper   +6 more
doaj   +2 more sources

Different expression of CD180, CD284 and CD14 receptors on the CD19+ subpopulation of normal and B-CLL lymphocytes.

Folia Histochemica et Cytobiologica, 2010
Numerous experimental data indicate that B-CLL development and progression are influenced by antigenic pressure. It can not be excluded that these antigens may originate from bacteria and viruses.
Barbara Marzec-Kotarska, Joanna Sajewicz, Halina Antosz, Janusz Kocki, Anna Dmoszyńska   +4 more
doaj   +4 more sources

Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system

Journal for ImmunoTherapy of Cancer
Background A bidirectional promoter-driven chimeric antigen receptor (CAR) cassette provides the simultaneous expression of two CARs, which significantly enhances dual antigen-targeted CAR T-cell therapy.Methods We developed a second-generation CAR ...
Supannikar Tawinwung, Nattiya Hirankarn, Asmita Khaniya, S M Ali Hossieni Rad, Josh Halpin, Alexander McLellan, Koramit Suppipat   +6 more
doaj   +2 more sources

Characterization of novel CD19-specific VHHs isolated from a camelid immune library by phage display

Journal of Translational Medicine, 2023
Background Monoclonal antibody (mAb)-based immunotherapies have achieved promising outcomes in the treatment of immunological and oncological indications. CD19 is considered one of the most qualified antigens in the treatment of B-cell neoplasms.
Mahmoud Ganji, Pooria Safarzadeh Kozani, Fatemeh Rahbarizadeh   +2 more
doaj   +2 more sources

Flow Cytometric Analysis of T, B, and NK Cells Antigens in Patients with Mycosis Fungoides [PDF]

Journal of Immunology Research, 2015
We retrospectively analyzed the clinicopathological correlation and prognostic value of cell surface antigens expressed by peripheral blood mononuclear cells in patients with mycosis fungoides (MF). 121 consecutive MF patients were included in this study.
Serkan Yazıcı, Emel Bülbül Başkan, Ferah Budak, Barbaros Oral, Şaduman Balaban Adim, Zübeyde Ceylan Kalin, Güven Özkaya, Kenan Aydoğan, Hayriye Saricaoğlu, Şükran Tunali   +9 more
doaj   +2 more sources

A rationally designed CD19 monoclonal antibody-triptolide conjugate for the treatment of systemic lupus erythematosus

Acta Pharmaceutica Sinica B
Tripterygium wilfordii Hook F (TWHF) is a traditional Chinese medicine widely used in the treatment of systemic lupus erythematosus (SLE), with triptolide (TP) as its main active ingredient.
Lai Wang, Haoyuan Yin, Jiao Jiang, Qilin Li, Changxing Gao, Wenrui Li, Bo Zhang, Yue Xin, Hongyang Li, Ming Zhao, Qianjin Lu   +10 more
doaj   +2 more sources

CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality

Scientific Reports, 2023
Tumor-derived extracellular vesicles (EVs) are active contributors in metastasis and immunosuppression in tumor microenvironment. At least some of the EVs carry tumor surface molecules such as tumor-associated antigens (TAAs) and/or checkpoint inhibitors,
V. M. Ukrainskaya, O. E. Musatova, D. V. Volkov, D. S. Osipova, D. S. Pershin, A. M. Moysenovich, E. G. Evtushenko, E. A. Kulakovskaya, E. G. Maksimov, H. Zhang, Y. P. Rubtsov, M. A. Maschan, A. V. Stepanov, A. G. Gabibov   +13 more
doaj   +2 more sources

Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency

The Journal of Clinical Investigation
While therapies targeting CD19 by antibodies, chimeric antigen receptor T cells (CAR-T), and T cell engagers have improved the response rates in B cell malignancies, the emergence of resistant cell populations with low CD19 expression can lead to ...
Sarah Aminov, Orsi Giricz, David T. Melnekoff, R. Alejandro Sica, Veronika Polishchuk, Cristian Papazoglu, Bonnie Yates, Hao-Wei Wang, Srabani Sahu, Yanhua Wang, Shanisha Gordon-Mitchell, Violetta V. Leshchenko, Carolina Schinke, Kith Pradhan, Srinivas Aluri, Moah Sohn, Stefan K. Barta, Beamon Agarwal, Mendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, William Matsui, Ulrich Steidl, Joshua D. Brody, Nirali N. Shah, Samir Parekh, Amit Verma   +26 more
doaj   +3 more sources

Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies

Journal of Immunology Research, 2021
Natural killer (NK) cells are part of the first line of defense that rapidly respond to malignant transformed cells. Chimeric antigen receptor- (CAR-) engineered NK cells, although are still at the preliminary stage, have been shown to be alternative to ...
Sudjit Luanpitpong, Jirarat Poohadsuan, Phatchanat Klaihmon, Surapol Issaragrisil   +3 more
doaj   +2 more sources